Currently, EpCAM has been FDA-approved as a diagnostic marker for breast, prostate, and colorectal cancers (Lin et al., 2021), and anti-EpCAM monoclonal antibodies have been approved in Europe for treating malignant ascites in EpCAM-positive cancer patients (Eyvazi et al., 2018). This evidence concerns the gene EPCAM and cancer.